Stay updated on HD IL-2 + Anti-PD-1 for Anti-PD-1 Resistant MM & RCC Clinical Trial
Sign up to get notified when there's something new on the HD IL-2 + Anti-PD-1 for Anti-PD-1 Resistant MM & RCC Clinical Trial page.

Latest updates to the HD IL-2 + Anti-PD-1 for Anti-PD-1 Resistant MM & RCC Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check13 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check20 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check28 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check56 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check64 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed study objectives and criteria for a clinical trial involving nivolumab and HD IL-2 for metastatic melanoma and renal cell carcinoma, while adding a new version revision and a mention of the study's location.SummaryDifference45%
Stay in the know with updates to HD IL-2 + Anti-PD-1 for Anti-PD-1 Resistant MM & RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HD IL-2 + Anti-PD-1 for Anti-PD-1 Resistant MM & RCC Clinical Trial page.